Autolus Brand Guidelines: A 2014 UCL Spin-Out, Obe-cel & a Stevenage Plant

A cancer researcher, a university and public research money.

Autolus began at University College London. It was founded in 2014 by Dr Martin Pule, a researcher at the UCL Cancer Institute, and spun out with the support of UCL Business, the university’s commercialisation company, according to an April 2025 news item from the NIHR UCLH Biomedical Research Centre. UK Research and Innovation, writing in November 2026, says the company licensed its CAR T-cell technology from UCL Ventures, the university’s commercialisation arm, and that its first programmes were aimed at rare forms of cancer.

The research behind it had public backing. UKRI says the foundations of Autolus were built on discovery research funded by the Biotechnology and Biological Sciences Research Council and the Medical Research Council; that the BBSRC also supported the spin-out itself; and that Innovate UK later funded work on scalable, commercially viable manufacturing processes for its therapies. UKRI first wrote about Autolus in 2016, when it described the business as a promising new spin-out.

The investor Syncona, which lists Autolus among its commercial-stage portfolio companies, gives the same founding year, names Christian Itin as chief executive and Pule as founder and chief scientific officer, and records a listing on Nasdaq in June 2018. Its portfolio page, with figures as of 30 June 2026, counts 752 employees and ten clinical trials. The company’s full name is Autolus Therapeutics; the FDA approval names the US company Autolus Inc., and the EMA names the European licence holder as Autolus GmbH.

Obe-cel and three regulators.

The company works on CAR T-cell therapy. In this approach, as UKRI explains it, a patient’s own immune cells are collected, genetically engineered so that they recognise cancer cells, and given back to the same patient; UKRI calls the treatment partly personalised, because each patient has a therapy manufactured specifically for them. Syncona describes Autolus as applying cell “programming” to develop autologous T-cell therapies for cancer and for autoimmune diseases.

Its first approved product is obecabtagene autoleucel, shortened to obe-cel and sold as Aucatzyl. On 8 November 2024 the US Food and Drug Administration approved it, under the name of Autolus Inc., as a CD19-directed, genetically modified autologous T-cell immunotherapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, according to the FDA’s announcement. The agency notes that the application had received regenerative medicine advanced therapy and orphan drug designations, and that its efficacy was evaluated in a trial named FELIX. The UCLH research centre notes that results from FELIX were published in the New England Journal of Medicine in November 2024, and names Dr Claire Roddie of the UCL Cancer Institute as the study’s lead investigator.

Britain followed. The Medicines and Healthcare products Regulatory Agency granted a conditional marketing authorisation on 25 April 2025, its press release says; the UCLH research centre called it the company’s first MHRA authorisation. In the European Union, the Committee for Medicinal Products for Human Use adopted its opinion on 22 May 2025 and the marketing authorisation was issued on 17 July 2025, according to the European Medicines Agency, which lists the holder as Autolus GmbH in Germany.

In England, the National Institute for Health and Care Excellence recommended obe-cel for NHS use in adults aged 26 and over with B-cell acute lymphoblastic leukaemia, and the first patient was treated with it through the NHS in January 2026, UKRI reported. UKRI adds that trials are under way in children with B-cell ALL and in systemic lupus erythematosus. Syncona’s pipeline chart lists further programmes under codes such as AUTO8, AUTO6NG and AUTO9, all at earlier stages.

Cells, vials and regulators.

Cell and gene therapy companies sell something that is hard to picture. A treatment may be a patient’s own cells, collected, changed in a laboratory and returned as a single dose, or a gene carried into the body by a modified virus. With no tablet or pack to show, these companies build their imagery from a small, shared set of motifs.

The most common is the abstract double helix, often drawn in light against a dark ground, followed closely by glowing cells, strands and particles rendered in soft blues, violets and teals. Where the science is shown more literally, the pictures move to the laboratory: gloved hands holding cryobags and vials, technicians in gowns, and clean manufacturing suites with stainless steel and bright, even light. Manufacturing matters to the story, because many of these treatments are made one patient at a time.

The other half of the visual language is human. Because most of these therapies are aimed at rare and inherited diseases, the companies lean on portraits of patients and their families, photographed at home or outdoors rather than in clinics, and on first-person stories told in their own words. Treatment centres, patient-support programmes and the steps of the “patient journey” often get as much space on a website as the science itself.

The field also has its own calendar. Companies present data and court investors and clinicians at meetings such as the annual meeting of the American Society of Gene & Cell Therapy (ASGCT), the American Society of Hematology (ASH) meeting in December, where blood-disorder therapies are discussed, and the Cell & Gene Meeting on the Mesa, an industry gathering. Names in the sector can change through spin-offs, sales and rebrands, so the identity a company shows at one meeting may not be the one it uses a few years later.

Made in Stevenage.

Where the therapy is made is documented. The NIHR UCLH Biomedical Research Centre wrote in April 2025 that Autolus had invested most of the money it raised in the UK, including a manufacturing facility called The Nucleus in Stevenage, Hertfordshire, employing 450 people. UKRI’s November 2026 account describes a new 70,000-square-foot manufacturing facility in the UK, where the company is headquartered, and adds that Autolus has expanded to locations in Switzerland, Germany and the United States. Christian Itin, quoted by the research centre in 2025, said the company’s scientific expertise, operations and manufacturing were based in the UK.

The way the company is described leans on its origins. UCL’s commercialisation arm, the investor Syncona and UKRI each present Autolus as an example of university research reaching the clinic, and UKRI says it has crossed the gap between the laboratory and a commercial product at which many start-up biopharma companies stall. Syncona and the UCLH research centre write the product name in capitals, AUCATZYL, with a registered-trademark sign, while regulators print it as Aucatzyl alongside the generic name.

For a design guide, Autolus shows how a university spin-out can present a single, highly technical therapy through the institutions that backed it, with the product name, the generic name and the short form obe-cel all in use at once. Compare Kite and Legend Biotech, two more cell-therapy companies in this series. For this guide we use a deep teal, a warm coral and a pale grey with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Autolus’s identity on hand — save it to a board in the Made Good inspiration library.